Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon‐induced hepatitis B e antigen seroconversion

Hung‐Chih Yang, Chi‐Ling Chen, Yueh‐Chi Shen, Cheng‐Yuan Peng, Chun‐Jen Liu, Tai‐Chung Tseng, Tung‐Hung Su, Wan‐Long Chuang, Ming‐Lung Yu, Chia‐Yen Dai, Chen‐Hua Liu, Pei‐Jer Chen, Ding‐Shinn Chen, Jia‐Horng Kao – 30 October 2012 – Precore (PC) (G1896A) and basal core promoter (BCP) (A1762T/G1764A) mutations of the hepatitis B virus (HBV) genome often emerge in chronic hepatitis B (CHB) patients. Their roles in hepatitis B e antigen (HBeAg) seroconversion induced by interferon (IFN) therapy remain controversial, partly because quantitative analysis for these mutants is lacking.

A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users

Arthur Y. Kim, Ellen H. Nagami, Christopher E. Birch, Melinda J. Bowen, Georg M. Lauer, Barbara H. McGovern – 30 October 2012 – Acute hepatitis C virus (HCV) infection is underdiagnosed because most patients are asymptomatic. The majority of new infections occur among people who inject drugs (PWID), many of whom have a history of incarceration. In a previous pilot study, we identified symptomatic HCV cases, mainly among Caucasian inmates.

Subscribe to